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repair with the Zenith TX2 endovascular graft: 1-year results
J.S. Matsumura, R.P. Cambria, M.D. Dake, R.D. Moore, L.G. Svensson and
S. Snyder for the TX2 Clinical Trial Investigators
Purpose. This trial evaluated the safety and effectiveness of thoracic endovas-
cular aortic repair (TEVAR) with a contemporary endograft system compared
with open surgical repair (open) of descending thoracic aortic aneurysms and
large ulcers.
Methods. Forty-two international trial sites enrolled 230 subjects with de-
scending thoracic aortic aneurysms or ulcers. The study compared 160 TE-
VAR subjects treated with the Zenith TX2 Endovascular Graft (William
Cook Europe, ApS, Bjaeverskov, Denmark) with 70 open subjects. Subjects
were evaluated preprocedure, predischarge, 1, 6, and 12 months, and yearly
through 5 years with medical examination, laboratory testing, chest radio-
graphs, and computed tomography scans. Mortality rates, prespecified se-
vere morbidity composite index, major morbidity, clinical utility, aneurysm
rupture, and secondary interventions were compared. The TEVAR subjects
were evaluated by a core laboratory for device performance, including
change in aneurysm size, endoleak, migration, and device integrity.
Results. The 30-day survival rate was noninferior (P< .01) for the TEVAR
group compared with the open group (98.1% vs 94.3%). The severe morbidity
composite index was lower for TEVAR (0.2 0.7 vs 0.7 1.2; P< .01). Cumula-
tive major morbidity scores were significantly lower at 30 days for the TEVAR
group compared with the open group (1.3 3.0 vs 2.9 3.6, P< .01). The TE-
VAR patients had fewer cardiovascular, pulmonary, and vascular adverse
events, although neurologic events were not significantly different. Clinical
utility for the TEVARpatientswas superior to that of the open patients. No rup-
tures or conversions occurred in the first year. Reintervention rateswere similar
in both groups. At 12months, aneurysmgrowthwas identified in 7.1% (8/112),
endoleak in 3.9% (4/103), migration (>10 mm) in 2.8% (3/107), and other de-
vice issues were rare. None of the patients with migration experienced endo-
leak, aneurysm growth, or required a secondary intervention.
Conclusion. Thoracic endovascular aortic repair with the TX2 is a safer and
effective alternative to open surgical repair for the treatment of anatomically
suitable descending thoracic aortic aneurysms and ulcers at 1 year of follow-
up. Device performance issues are infrequent, but careful planning and reg-
ular follow-up with imaging remain a necessity.Colon ischemia following abdominal aortic aneurysm repair
in the era of endovascular abdominal aortic repair
J.-P. Becquemin, M. Majewski, N. Fermani, J. Marzelle, P. Desgrandes,
E. Allaire and F. Roudot-Thoraval
Objective. To review, in the era of endovascular abdominal aortic repair
(EVAR), the clinical spectrum of colonic ischemia (CI) following abdominal
aortic aneurysm (AAA) repair and to assess the rate, overall mortality, and
associated factors of occurrence.
Methods. Between 1995 and 2005, 1174 patients with infrarenal AAA were
treated either by open surgery (n¼ 682) or by EVAR (n¼ 492). Preoperative
risk factors, clinical presentation, intraoperative data, and early postoperative
outcomes were prospectively assessed. Overt colonic ischemia as proven by
colonoscopy and/or by operation was considered as a validating event and
was correlated to collected variables.
Results. CI occurred in 34 patients (2.9%). Eighteen out of 34 (53%) patients
died within 1 month. At 2 years, the survival rate was 35% in the CI group vs
86% in the non-CI group. Associated factors of occurrence of CI were: type of
operation (open group¼ 27/682 [4%] vs EVAR¼ 7/492 [1.4%] [P¼ .01]),
aneurysm rupture (11/88 [12.5%] vs 23/1086 [2.1%], P< .001), preoperative
renal insufficiency (4/30 [13.3%] vs 29/1133 [3.1%], P¼ .01), preoperative
respiratory insufficiency (8/157 [7%] vs 23/1005 [2%], P¼ .01), duration of
operation (<2 hours [518]¼ 1.7%, between 2 to 4 hours [558] 2.9%, more than
4 hours [66] 13.6%, P¼ .001). Mean blood loss was greater in patients with CIYEJVS3032_3008_proof  14
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P¼ .008). Logistic regression analysis showed that rupture (OR 6.03 [interval
of confidence (IC) 95% 2.68-13.5] P¼ .0001), duration of operation (OR 5.73
[IC 95% 2.06-15.9] P¼ .001) and creatinin > 200 mol/l (OR 4.67 [IC 95%
1.39-15.7] P¼ .028) were independent factors of CI. The mortality due to co-
lonic ischemia was not statistically different between open surgery 14/27
(52%) and EVAR 4/7 (57%).
Conclusion. CI remains a serious complication following AAA repair. In the
univariate analysis, EVARwas associatedwith a lower rate of colonic ischemia.
However, the logistic regression analysis showed that only rupture, long dura-
tion of operation, and prior renal disease were independently associated with
CI. Within the two treatment modalities, the mortality rate remained identical.The incidence and factors associated with graft infection after aortic
aneurysm repair
T.R. Vogel, R. Symons and D.R. Flum
Objectives. The reported rate of abdominal aortic graft infections (AGIs) is
low, but its incidence and associated factors have not been evaluated on
a population level. We hypothesized that AGI occurs more often in patients
with periprocedural nosocomial infections and less often after endovascular
aneurysm repair (EVAR).
Methods. A retrospective cohort study was done of all patients undergoing
abdominal aortic aneurysm (AAA) repair (1987-2005) in Washington State
by using the Comprehensive Hospital Abstract Reporting System (CHARS)
data. Nosocomial infection was defined as one or more of pneumonia, uri-
nary tract infections, blood stream septicemia, or surgical site infection at
the index admission. Readmissions and reintervention for graft infections
defined AGIs excluding the diagnostic code of renal failure or those who
appeared to have dialysis grafts.
Results. Between 1987 and 2005, 13,902 patients (mean age, 71.3 8.8 years;
90.8% men) underwent AAA repair (12,626 open, 1276 EVAR). The cumula-
tive rate of AGIs in the cohort was 0.44%. The 2-year rate of AGI was 0.19%
among open vs 0.16% in EVAR (P¼ .75) and 0.2% in both elective and non-
elective patients. Open procedures had greater rates of perioperative pneu-
monia (11.1% vs 2.4%, P< .001), blood stream septicemia (1.6% vs 0.7%,
P< .01), and surgical site infection (.5% vs 0%, P< .012) compared with
EVAR. When individually analyzed, blood stream septicemia (.93% vs 18%,
P¼ .014) and surgical site infection (1.61% vs 0.19%, P¼ .01) were signifi-
cantly associated with AGIs. The median time to AGI was 3.0 years, and
AGI presented sooner (1.4 years) if nosocomial infection occurred at the in-
dex admission. This risk of developing AGI after open repair was highest in
the first postoperative year (32% of all AGI occurred in year 1). In an adjusted
model, blood stream septicemia was significantly associated with AGI (odds
ratio, 4.2; 95% confidence interval, 1.5-11.8).
Conclusions. The incidence of AGI was low, presented most commonly in the
first postoperative year, and was similar among patients undergoing open
AAA repair and EAVR. Patients with nosocomial infection had an earlier on-
set of AGI. The 2-year rate of AGI was significantly higher in patients who
had blood stream septicemia and surgical site infection in the periprocedural
hospitalization. These data may be helpful in directing surveillance programs
for AIG.Detection of intraplaque hemorrhage by magnetic resonance imaging in
symptomatic patients with mild to moderate carotid stenosis predicts
recurrent neurological events
N. Altaf, L. Daniels, P.S. Morgan, D. Auer, S.T. MacSweeney,
A.R. Moody and J.R. Gladman
Background. Carotid endarterectomy is beneficial in severe (>70%) symp-
tomatic carotid stenosis. The risk of stroke in moderate carotid stenosis
(50%-69%) is modest, and so the role of carotid endarterectomy in this
group is unclear. Intraplaque hemorrhage is associated with advancedJanuary 2008  246/248
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247Abstractsatherosclerosis and can be detected in the carotid arteries by magnetic reso-
nance imaging. This study evaluates whether magnetic resonance imaging
detected intraplaque hemorrhage (MR IPH) can identify patients with symp-
tomatic mild to moderate carotid stenosis who are at higher risk of ipsilateral
transient ischemic attack (TIA) and stroke.
Methods. Prospective longitudinal cohort study of symptomatic patients with
mild to moderate (30%-69%) carotid stenosis followed up for 2 years after
imaging for IPH using magnetic resonance imaging.
Results. Sixty four participants were followed up for a median of 28 months
(interquartile range 26-30) after MRI of the carotid arteries. Thirty-nine (61%)
ipsilateral arteries showed intraplaque hemorrhage. During follow-up, five
ipsilateral strokes and a total of 14 ipsilateral ischemic events were observed.
Thirteen of these ischemic events, of which five were strokes, occurred in
those with ipsilateral carotid intraplaque hemorrhage (hazard ratio¼ 9.8,
95% confidence interval 1.3-75.1, P¼ .03).
Conclusions. MR IPH is a good predictor of ipsilateral stroke and TIA in
patients with symptomatic mild to moderate (30%-69%) carotid stenosis.
This technique could help in the selection of patients for carotid
endarterectomy.Clinical results of carotid artery stenting compared with
carotid endarterectomy
S. Brahmanandam, E.L. Ding, M.S. Conte, M. Belkin and L.L. Nguyen
Objectives. Carotid artery stenting (CAS) is an alternative to carotid endarter-
ectomy (CEA) for treating carotid artery stenosis. We conducted a systematic
review and meta-analysis of the clinical trials to date comparing these two
procedures to determine their relative safety and efficacy.
Methods. Searches of the Cochrane Controlled Trials Register, MEDLINE, and
EMBASE identified two cohort studies and eight randomized, controlled trials
(RCTs) comparing CEA and CAS. Meta-analysis was performed for the pri-
mary outcome of 30-day stroke or death, using an intention-to-treat analysis.
Between-trial heterogeneity was assessed using the c2 test, and fixed-effects
models were used to pool estimates in the absence of heterogeneity. Meta-
regression was conducted to investigate potential effect differences by patient,
intervention, and trial characteristics. To evaluate the effect of study design and
inclusion criteria, sensitivity and subgroup analyses were performed.
Results. Ten trials encompassing 3580 patients were analyzed. Patients who
underwent CAS had a higher risk of 30-day stroke/death relative to pa-
tients who underwent CEA (risk ratio [RR], 1.30; 95% CI, 1.01-1.67). Meta-
analysis and meta-regression demonstrated no between-trial heterogeneity.
Sensitivity analysis of only RCTs showed similar higher risk for stroke/
death (RR, 1.38; 95% CI, 1.06-1.79) in CAS patients. Subgroup analysis of
trials enrolling only symptomatic patients showed higher risk of 30-day
stroke/death (RR, 1.63; 95% CI, 1.18-2.25), but trials enrolling both symp-
tomatic and asymptomatic patients showed no significant differences (RR,
0.89; 95% CI, 0.59-1.35).
Conclusions. Meta-analysis of trials to date shows CAS is associated with
higher 30-day risk of stroke/death compared with CEA. Thus, for the patient
at average surgical risk, the role of CAS is unproven, especially for symptom-
atic patients. And for the patient at high surgical risk, the role of any interven-
tion is uncertain in the setting of competing comorbidities. The results of
ongoing clinical trials in this area will likely provide additional evidence to
support treatment choices for carotid artery stenosis.Benign superior vena cava syndrome: Stenting is now the
first line of treatment
A.Z. Rizvi, M. Kalra, H. Bjarnason, T.C. Bower, C. Schleck and P. Gloviczki
Background. Endovascular repair (EVR) is emerging as first-line treatment for
patients with superior vena cava (SVC) syndrome of benign etiology, but data
on its durability remain scarce. The aims of this study were to assess the ef-
ficacy and durability of EVR and compare results of EVR with open surgical
reconstruction (OSR).
Methods. Data from 70 consecutive patients undergoing treatment for benign
SVC syndrome between November 1983 and November 2006 were retrospec-
tively reviewed.Results. There were 30 males and 40 females (mean age, 41 years; range,
5-75 years). Etiology included indwelling catheters or pacemaker wires in
35 patients, mediastinal fibrosis in 31, idiopathic thrombosis in 2, hyperco-
agulable disorder in 1, and postsurgical thrombosis in 1. In 42 patients, OSR
was done through a median sternotomy: repair was with spiral saphenous
vein in 22, expanded polytetrafluoroethylene (ePTFE) in 13, femoral vein
grafts in 6, and human allograft in 1. Fifteen OSRs followed failed EVR in-
terventions. EVR was attempted in 32 patients and was successful in 28
(88%): 19 had stenting, 14 had percutaneous transluminal balloon angio-
plasty (PTA), 2 had thrombolytic therapy with PTA, and 3 had stenting.
All four technical failures subsequently underwent OSR. There were no
early deaths in either group. Periprocedural morbidity was 19% after OSR
and 4% in the EVR group. Six early surgical graft failures were successfully
treated with surgical revision; one restenosis after EVR was restented. Dur-
ing a mean follow-up of 4.1 years (range, 0.1-17.5 years) after OSR, 11 pa-
tients underwent 18 secondary interventions. Mean follow-up after EVR
was 2.2 years (range, 0.2-6.4 years), and nine patients underwent 21 second-
ary EVR interventions. Primary, assisted primary, and secondary patency
rates of surgical bypass grafts were, respectively, 45%, 68%, and 75% at 3
and 5 years. Primary, assisted primary and secondary patency rates after
EVR were 44%, 96%, and 96% at 3 years. Assisted primary patency was
significantly higher in vein grafts than in ePTFE grafts (P¼ .05). Assisted
primary and secondary patency was significantly higher in patients
undergoing stenting compared with PTA (P¼ .02). At last follow-up, 93%
of patients in both OSR and EVR groups had significant relief from
symptoms.
Conclusions. OSR of benign SVC syndrome is effective, with durable long-
term relief from symptoms. EVR is less invasive but equally effective in the
mid-term, albeit at the cost of multiple secondary interventions, and is an
appropriate primary treatment for benign SVC syndrome. OSR remains an
excellent choice for patients who are not suitable for EVR or in whom the
EVR fails.Late results of surgical venous thrombectomy with iliocaval stenting
O. Hartung, F. Benmiloud, P. Barthelemy, M. Dubuc, M. Boufi and Y.S. Alimi
Purpose. Iliac vein occlusive disease leads to 73% of rethrombosis that occurs
after venous thrombectomy when left untreated. The goal of this study is to
present our long-term results of stenting of iliocaval occlusive lesions persist-
ing after surgical venous thrombectomy.
Methods. From November 1995 to April 2007, 29 patients (19 women),
with a median age of 38 years, had surgical venous thrombectomy with
creation of an arteriovenous fistula and angioplasty and stenting. All
were admitted for acute (<10 days) deep venous thrombosis (DVT) involv-
ing the iliocaval segment, of which eight had concomitant acute pulmo-
nary embolism. Six patients had a history of DVT (2 with previous
venous thrombectomy), two were pregnant, and three had postpartum
DVT. No patients had short- or mid-term life-threatening factors. The un-
derlying lesion was left iliocaval compression (May-Thurner syndrome) in
22 patients, chronic left common iliac vein occlusion in 3, residual clot in
3, and compression of the left external iliac vein by the left internal iliac
artery in 1.
Results. Neither perioperative death nor pulmonary embolism occurred.
Four early complications occurred after stenting (13.8%). Median hospital
length of stay was 8 days (range, 5-22 days). Median follow-up was 63
months (range, 2-137 months). Three late complications occurred (10.3 %):
one rethrombosis due to stent crushing during pregnancy and two restenosis,
which were treated by iterative stenting. At the end of the follow-up, the me-
dian venous clinical severity score was 3 (range 1-12) and the venous disabil-
ity score was 1 (range 0-2). Primary, assisted primary and secondary patency
rates were, respectively, 79%, 86%, and 86% at 12, 60, and 120 months. Pa-
tients with patent iliocaval segments had significantly fewer infrainguinal ob-
structive lesions (4% vs 50%) and a higher rate of valvular competence (76%
vs 0%) than those who experienced rethrombosis. Venous scores were also
worse in patients with rethrombosis.
Conclusion. Stenting is a safe, efficient, and durable technique to treat occlu-
sive iliocaval disease after venous thrombectomy. Its use can prevent most of
the rethrombosis that occurrs after venous thrombectomy without major ad-
verse effects.Eur J Vasc Endovasc Surg Vol 35, February 2008
248 AbstractsA randomized multicenter study of the outcome of brachial-basilic
arteriovenous fistula and prosthetic brachial-antecubital forearm loop
as vascular access for hemodialysis
Xavier H.A. Keuter, Andre´ A.E.A. De Smet, Alfons G.H. Kessels, Frank M. van
der Sande, Rob J.Th.J. Welten and Jan H.M. Tordoir
Background. Vascular access is a necessity for patients with end-stage renal
disease who need chronic intermittent hemodialysis. According to Kidney
Disease Outcomes Quality Initiative (KDOQI) guidelines, radial-cephalic
(RC) and brachial-cephalic (BC) arteriovenous fistulas (AVF) are the first
and second choice for vascular access, respectively. If these options are not
possible, an autogenous brachial-basilic fistula in the upper arm (BBAVF)
or a prosthetic brachial-antecubital forearm loop (PTFE loop) may be consid-
ered. Until now, it was not clear which access type was preferable. We have
performed a randomized study comparing BBAVF and prosthetic implanta-
tion in patients without the possibility for RCAVF or BCAVF.
Methods. Patients with failed primary/secondary access or inadequate arte-
rial and/or venous vessels were randomized for either BBAVF or PTFE loop
creation. The numbers of complications and interventions were recorded.
Kaplan-Meier method was used to calculate primary, assisted-primary andEur J Vasc Endovasc Surg Vol 35, February 2008secondary patency rates. The patency rates were compared with the log-
rank test. Complication and intervention rates were compared with the
Mann-Whitney test.
Results. A total of 105 patients were randomized for a BBAVF or PTFE loop
(52 vs 53, respectively). Primary and assisted-primary 1-year patency rates
were significantly higher in the BBAVF group: 46% 7.4% vs 22% 6.1%
(P¼ .005) and 87% 5.0% vs 71% 6.7% (P¼ .045) for the BBAVF and
PTFE group, respectively. Secondary patencies were comparable for both
groups; 89% 4.6% vs 85% 5.2% for the BBAVF and PTFE group, respec-
tively. The incidence rate of complications was 1.6 per patient-year in the
BBAVF group vs 2.7 per patient-year in the PTFE group. Patients in the
BBAVF group needed a total of 1.7 interventions per patient-year vs 2.7 per
patient-year for the PTFE group.
Conclusion. These data show a significantly better primary and assisted-pri-
mary patency in the BBAVF group compared with the PTFE group. Further-
more, in the BBAVF group, fewer interventions were needed. Therefore, we
conclude that BBAVF is the preferred choice for vascular access if RCAVF
or BCAVF creation is impossible, or when these types of access have already
failed.
